Your browser is no longer supported. Please, upgrade your browser.
SNY [NASD]
Sanofi
Index- P/E8.73 EPS (ttm)5.42 Insider Own16.40% Shs Outstand2.50B Perf Week-5.17%
Market Cap118.18B Forward P/E12.54 EPS next Y3.77 Insider Trans0.00% Shs Float2.25B Perf Month-0.25%
Income13.65B PEG1.16 EPS next Q0.69 Inst Own7.00% Short Float0.15% Perf Quarter-3.66%
Sales45.79B P/S2.58 EPS this Y-32.80% Inst Trans-0.17% Short Ratio1.71 Perf Half Y-8.68%
Book/sh26.25 P/B1.80 EPS next Y10.32% ROA- Target Price64.67 Perf Year-1.95%
Cash/sh- P/C- EPS next 5Y7.50% ROE- 52W Range37.62 - 55.00 Perf YTD-2.59%
Dividend1.70 P/FCF- EPS past 5Y-6.40% ROI3.50% 52W High-13.95% Beta0.54
Dividend %3.59% Quick Ratio- Sales past 5Y3.30% Gross Margin67.70% 52W Low25.81% ATR0.81
Employees100409 Current Ratio- Sales Q/Q-0.40% Oper. Margin39.00% RSI (14)39.15 Volatility1.58% 1.27%
OptionableYes Debt/Eq- EPS Q/Q4.30% Profit Margin34.30% Rel Volume1.22 Prev Close49.15
ShortableYes LT Debt/Eq- EarningsFeb 05 BMO Payout0.00% Avg Volume1.92M Price47.33
Recom1.40 SMA20-3.07% SMA50-3.71% SMA200-5.19% Volume2,348,868 Change-3.70%
Jan-15-21Initiated Deutsche Bank Sell
Sep-29-20Initiated Berenberg Hold
Mar-17-20Upgrade Barclays Underweight → Equal Weight
Mar-11-20Upgrade Goldman Neutral → Buy
Feb-11-20Initiated SVB Leerink Mkt Perform
Jan-06-20Upgrade JP Morgan Neutral → Overweight
Sep-23-19Upgrade Guggenheim Neutral → Buy
Sep-20-19Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19Initiated Bernstein Outperform
Aug-14-19Upgrade UBS Neutral → Buy
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Jan-27-21 10:09AM  
08:50AM  
08:05AM  
07:35AM  
07:00AM  
05:02AM  
02:00AM  
01:35AM  
Jan-26-21 12:00PM  
Jan-25-21 09:49AM  
Jan-19-21 03:15PM  
Jan-18-21 06:13AM  
Jan-15-21 11:54AM  
08:14AM  
Jan-13-21 01:44PM  
Jan-12-21 02:10PM  
08:30AM  
08:00AM  
07:05AM  
Jan-11-21 05:18PM  
08:40AM  
06:41AM  
02:30AM  
Jan-08-21 09:11AM  
06:02AM  
Jan-07-21 11:00AM  
Jan-06-21 12:00AM  
Dec-28-20 10:39AM  
Dec-22-20 10:22AM  
Dec-21-20 10:50AM  
07:00AM  
Dec-18-20 08:41AM  
Dec-17-20 04:30PM  
Dec-16-20 06:03AM  
Dec-15-20 11:49AM  
10:12AM  
01:00AM  
Dec-14-20 03:26PM  
Dec-11-20 04:14PM  
11:16AM  
10:37AM  
10:10AM  
09:29AM  
08:30AM  
08:11AM  
07:09AM  
03:20AM  
02:04AM  
01:37AM  
01:00AM  
01:00AM  
Dec-09-20 01:00AM  
Dec-07-20 04:38PM  
Dec-03-20 06:38AM  
Dec-02-20 11:17AM  
Nov-30-20 04:38PM  
04:16PM  
02:39PM  
01:28AM  
01:00AM  
Nov-24-20 01:36PM  
12:05PM  
11:12AM  
Nov-23-20 04:08PM  
01:59PM  
11:34AM  
11:12AM  
04:00AM  
Nov-20-20 09:44AM  
08:42AM  
Nov-19-20 09:16AM  
Nov-18-20 01:12PM  
07:29AM  
01:29AM  
01:15AM  
01:00AM  
Nov-16-20 01:54PM  
10:04AM  
08:18AM  
07:57AM  
Nov-13-20 07:00PM  
07:40AM  
01:09AM  
Nov-10-20 04:46PM  
07:30AM  
Nov-05-20 04:10PM  
12:55PM  
09:42AM  
Nov-04-20 06:50AM  
Nov-03-20 09:11AM  
Nov-02-20 06:09AM  
03:42AM  
01:15AM  
Oct-30-20 05:00PM  
01:06PM  
11:23AM  
Oct-29-20 12:12PM  
09:50AM  
06:28AM  
05:43AM  
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 28Buy16.0081,2501,300,000520,125Jul 29 06:06 AM
Sanofi10% OwnerJun 09Sale597.48120,23471,837,410279,766Jun 11 06:45 PM
Sanofi10% OwnerMay 29Sale509.852,399,5521,223,411,587400,000May 29 04:16 PM
Sanofi10% OwnerMay 29Sale509.8520,421,89910,412,105,2050May 29 04:16 PM
Sanofi10% OwnerMar 09Sale489.65128,91463,123,15320,421,899Mar 11 05:00 PM